Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	N6-methyladenosine-containing RNA reader activity	IGF2BP1 IGF2BP3 IGF2BP2	2.43e-05	15	77	3	GO:1990247
GeneOntologyMolecularFunction	protein-RNA adaptor activity	IGF2BP1 IGF2BP3 IGF2BP2	1.05e-04	24	77	3	GO:0140517
GeneOntologyMolecularFunction	mRNA 5'-UTR binding	IGF2BP1 IGF2BP3 IGF2BP2	1.19e-04	25	77	3	GO:0048027
GeneOntologyBiologicalProcess	CRD-mediated mRNA stabilization	IGF2BP1 IGF2BP3 IGF2BP2	8.08e-06	11	77	3	GO:0070934
GeneOntologyBiologicalProcess	chromosome organization involved in meiotic cell cycle	ANKRD31 NCAPD3 SYCP2 HORMAD1 RAD50	8.95e-06	75	77	5	GO:0070192
MousePheno	abnormal cell nucleus morphology	PDS5B SYNE2 FEN1 TOPORS TRIM24 HORMAD1 RAD54L	2.01e-05	184	64	7	MP:0003111
MousePheno	abnormal chromosome morphology	PDS5B FEN1 TOPORS TRIM24 HORMAD1 RAD54L	2.33e-05	126	64	6	MP:0003702
MousePheno	abnormal chromosome number	PDS5B FEN1 TOPORS TRIM24 HORMAD1	4.49e-05	86	64	5	MP:0004023
Domain	GOLGA6L	GOLGA6L10 GOLGA6L19 GOLGA6L9 GOLGA6L4	4.42e-09	6	79	4	IPR026737
Domain	GOLGA2L5	GOLGA6L10 GOLGA6L19 GOLGA6L9 GOLGA6L4	8.67e-07	18	79	4	PF15070
Domain	Golgin_A	GOLGA6L10 GOLGA6L19 GOLGA6L9 GOLGA6L4	8.67e-07	18	79	4	IPR024858
Domain	KH_1	IGF2BP1 IGF2BP3 IGF2BP2	5.52e-04	38	79	3	PF00013
Domain	-	IGF2BP1 IGF2BP3 IGF2BP2	5.96e-04	39	79	3	3.30.1370.10
Domain	rSAM	TYW1 CDKAL1	6.24e-04	9	79	2	IPR007197
Domain	Radical_SAM	TYW1 CDKAL1	6.24e-04	9	79	2	PF04055
Domain	KH	IGF2BP1 IGF2BP3 IGF2BP2	6.43e-04	40	79	3	SM00322
Domain	KH_dom	IGF2BP1 IGF2BP3 IGF2BP2	6.43e-04	40	79	3	IPR004087
Domain	KH_TYPE_1	IGF2BP1 IGF2BP3 IGF2BP2	7.42e-04	42	79	3	PS50084
Domain	KH_dom_type_1	IGF2BP1 IGF2BP3 IGF2BP2	8.51e-04	44	79	3	IPR004088
Domain	Myosin_N	MYH2 MYH8	1.79e-03	15	79	2	PF02736
Domain	Myosin_N	MYH2 MYH8	1.79e-03	15	79	2	IPR004009
Domain	Myosin_tail_1	MYH2 MYH8	2.59e-03	18	79	2	PF01576
Domain	Myosin_tail	MYH2 MYH8	2.59e-03	18	79	2	IPR002928
Domain	Myosin-like_IQ_dom	MYH2 MYH8	2.88e-03	19	79	2	IPR027401
Domain	-	MYH2 MYH8	2.88e-03	19	79	2	4.10.270.10
Domain	HEAT_REPEAT	PIK3R4 PDS5B NCAPD3	3.25e-03	70	79	3	PS50077
Domain	-	CEP95 SYNE2 UTRN	3.39e-03	71	79	3	1.10.418.10
Domain	FCH	SRGAP3 PACSIN3	3.86e-03	22	79	2	PF00611
Domain	FCH	SRGAP3 PACSIN3	3.86e-03	22	79	2	SM00055
Domain	CH-domain	CEP95 SYNE2 UTRN	3.95e-03	75	79	3	IPR001715
Domain	Actinin_actin-bd_CS	SYNE2 UTRN	4.22e-03	23	79	2	IPR001589
Domain	Spectrin	SYNE2 UTRN	4.22e-03	23	79	2	PF00435
Domain	ACTININ_2	SYNE2 UTRN	4.22e-03	23	79	2	PS00020
Domain	FCH_dom	SRGAP3 PACSIN3	4.22e-03	23	79	2	IPR001060
Domain	ACTININ_1	SYNE2 UTRN	4.22e-03	23	79	2	PS00019
Domain	F_BAR	SRGAP3 PACSIN3	4.98e-03	25	79	2	IPR031160
Domain	F_BAR	SRGAP3 PACSIN3	4.98e-03	25	79	2	PS51741
Domain	ACR	ADAMTS5 ADAM28	5.79e-03	27	79	2	SM00608
Domain	ADAM_Cys-rich	ADAMTS5 ADAM28	5.79e-03	27	79	2	IPR006586
Domain	Spectrin_repeat	SYNE2 UTRN	6.66e-03	29	79	2	IPR002017
Domain	Spectrin/alpha-actinin	SYNE2 UTRN	8.07e-03	32	79	2	IPR018159
Domain	SPEC	SYNE2 UTRN	8.07e-03	32	79	2	SM00150
Pubmed	IGF2BP1, IGF2BP2 and IGF2BP3 genotype, haplotype and genetic model studies in metabolic syndrome traits and diabetes.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	20627640
Pubmed	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	17296566
Pubmed	Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	29476152
Pubmed	Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	16049158
Pubmed	A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	9891060
Pubmed	VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	15601260
Pubmed	Initiation of stress granule assembly by rapid clustering of IGF2BP proteins upon osmotic shock.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	32668274
Pubmed	ZBP1 recognition of beta-actin zipcode induces RNA looping.	IGF2BP1 IGF2BP3 IGF2BP2	1.26e-08	3	82	3	20080952
Pubmed	The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	27184842
Pubmed	H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	10875929
Pubmed	mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	21576258
Pubmed	Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	15225648
Pubmed	miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	26160756
Pubmed	IMP2 axonal localization, RNA interactome, and function in the development of axon trajectories.	IGF2BP1 IGF2BP3 IGF2BP2	5.04e-08	4	82	3	27385015
Pubmed	circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.	IGF2BP1 IGF2BP3 IGF2BP2	2.51e-07	6	82	3	33436560
Pubmed	METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression.	IGF2BP1 IGF2BP3 IGF2BP2	1.05e-06	9	82	3	37340443
Pubmed	Replication of recently described type 2 diabetes gene variants in a South Indian population.	MLXIPL IGF2BP2 CDKAL1	3.55e-06	13	82	3	20580033
Pubmed	Insights into specificity, redundancy and new cellular functions of C/EBPa and C/EBPb transcription factors through interactome network analysis.	IGF2BP1 IGF2BP3 WDR37 CAVIN2 RAD50	3.87e-06	99	82	5	27746211
Pubmed	Defective excitation-contraction coupling is partially responsible for impaired contractility in hindlimb muscles of Stac3 knockout mice.	MYH2 MYH8 TNNT3	4.51e-06	14	82	3	27184118
Pubmed	A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking.	IGF2BP1 IGF2BP2	5.49e-06	2	82	2	11713986
Pubmed	Insulin-like growth factor II mRNA binding protein 1 modulates Rev-dependent human immunodeficiency virus type 1 RNA expression.	IGF2BP1 IGF2BP2	5.49e-06	2	82	2	19726068
Pubmed	Contribution of CDKAL1 rs7756992 and IGF2BP2 rs4402960 polymorphisms in type 2 diabetes, diabetic complications, obesity risk and hypertension in the Tunisian population.	IGF2BP2 CDKAL1	5.49e-06	2	82	2	24636221
Pubmed	Nuclear transit of human zipcode-binding protein IMP1.	IGF2BP1 IGF2BP3	5.49e-06	2	82	2	12921532
Pubmed	The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis.	IGF2BP1 IGF2BP3	5.49e-06	2	82	2	11992722
Pubmed	RNA-binding IMPs promote cell adhesion and invadopodia formation.	IGF2BP1 IGF2BP3	5.49e-06	2	82	2	16541107
Pubmed	Slow and fast fiber isoform gene expression is systematically altered in skeletal muscle of the Sox6 mutant, p100H.	MYH2 MYH8 TNNT3	8.39e-06	17	82	3	16124007
Pubmed	CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.	IGF2BP1 IGF2BP3 SYNE2	1.00e-05	18	82	3	33361760
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	PDS5B NCAPD3 IGF2BP1 IGF2BP3 IGF2BP2 TMA16 SEPTIN14 FEN1 PRPF38B CGGBP1 TRIM24 RAD50	1.05e-05	1103	82	12	34189442
Pubmed	IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.	IGF2BP3 IGF2BP2	1.64e-05	3	82	2	29217458
Pubmed	Structural basis for Spt5-mediated recruitment of the Paf1 complex to chromatin.	RTF1 SUPT5H	1.64e-05	3	82	2	24101474
Pubmed	A genome-wide association study of gestational diabetes mellitus in Korean women.	IGF2BP2 CDKAL1	1.64e-05	3	82	2	22233651
Pubmed	SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations.	IGF2BP2 CDKAL1	1.64e-05	3	82	2	18711366
Pubmed	m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia.	IGF2BP3 IGF2BP2	1.64e-05	3	82	2	38572589
Pubmed	Interaction analysis of miR-1275/IGF2BP1/IGF2BP3 with the susceptibility to hepatocellular carcinoma.	IGF2BP1 IGF2BP3	1.64e-05	3	82	2	32134323
Pubmed	Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study.	IGF2BP1 CDKAL1	1.64e-05	3	82	2	18252897
Pubmed	Association analysis of IGF2BP2, KCNJ11, and CDKAL1 polymorphisms with type 2 diabetes mellitus in a Moroccan population: a case-control study and meta-analysis.	IGF2BP2 CDKAL1	1.64e-05	3	82	2	24898818
Pubmed	An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis.	IGF2BP1 IGF2BP2	1.64e-05	3	82	2	32245947
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	ABCC3 MYH2 NCAPD3 COQ8A SYNE2 DLGAP5 TRIM24 HORMAD1 CAVIN2	1.98e-05	638	82	9	31182584
Pubmed	Fibril treatment changes protein interactions of tau and α-synuclein in human neurons.	IGF2BP1 IGF2BP3 SACS SRGAP3 SYNE2 FEN1 WDR37 RAD50	2.36e-05	498	82	8	36634849
Pubmed	TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.	SYCP2 HORMAD1	3.28e-05	4	82	2	39207914
Pubmed	Evaluation of embryonic and perinatal myosin gene mutations and the etiology of congenital idiopathic clubfoot.	MYH2 MYH8	3.28e-05	4	82	2	20357587
Pubmed	Genetic modifiers of cystic fibrosis-related diabetes.	IGF2BP2 CDKAL1	3.28e-05	4	82	2	23670970
Pubmed	Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis.	MFN2 UTRN	3.28e-05	4	82	2	12499352
Pubmed	MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206.	FSTL1 UTRN	3.28e-05	4	82	2	17030984
Pubmed	Synemin acts as a regulator of signalling molecules during skeletal muscle hypertrophy.	MYH2 MYH8 RPS6KB1	3.97e-05	28	82	3	25179606
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	PDS5B IGF2BP1 IGF2BP3 IGF2BP2 TMA16 SACS SUPT5H FEN1 PRPF38B CGGBP1 NKAPL	4.67e-05	1082	82	11	38697112
Pubmed	Sequential accumulation of mRNAs encoding different myosin heavy chain isoforms during skeletal muscle development in vivo detected with a recombinant plasmid identified as coding for an adult fast myosin heavy chain from mouse skeletal muscle.	MYH2 MYH8	5.47e-05	5	82	2	6196357
Pubmed	Developmental pattern of mouse skeletal myosin heavy chain gene transcripts in vivo and in vitro.	MYH2 MYH8	5.47e-05	5	82	2	3829126
Pubmed	Myosin heavy chain isoforms of the murine masseter muscle during pre- and post-natal development.	MYH2 MYH8	5.47e-05	5	82	2	12919077
Pubmed	HectD1 controls hematopoietic stem cell regeneration by coordinating ribosome assembly and protein synthesis.	IGF2BP1 IGF2BP3 IGF2BP2 UTRN	5.50e-05	87	82	4	33711283
Pubmed	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.	RTF1 PIK3R4 MYH2 MYH8 NKAPD1 RPS6KB1 NKAPL UTRN GLCCI1 RAD50	5.59e-05	910	82	10	36736316
Pubmed	A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties.	IGF2BP1 IGF2BP3 IGF2BP2	5.96e-05	32	82	3	24192035
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	RFTN1 DSC3 PACSIN3 RELL1 WDR37 UTRN CDKAL1	6.31e-05	421	82	7	36976175
Pubmed	Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan.	IGF2BP2 CDKAL1	8.19e-05	6	82	2	18477659
Pubmed	Distinct myogenic programs of embryonic and fetal mouse muscle cells: expression of the perinatal myosin heavy chain isoform in vitro.	MYH2 MYH8	8.19e-05	6	82	2	1728586
Pubmed	Ensuring meiotic DNA break formation in the mouse pseudoautosomal region.	ANKRD31 HORMAD1	8.19e-05	6	82	2	32461690
Pubmed	Organization of human and mouse skeletal myosin heavy chain gene clusters is highly conserved.	MYH2 MYH8	8.19e-05	6	82	2	10077619
Pubmed	MURC/Cavin-4 facilitates recruitment of ERK to caveolae and concentric cardiac hypertrophy induced by α1-adrenergic receptors.	ADRA1A CAVIN2	8.19e-05	6	82	2	24567387
Pubmed	Spatial and temporal changes in myosin heavy chain gene expression in skeletal muscle development.	MYH2 MYH8	8.19e-05	6	82	2	10588881
Pubmed	Molecular composition of IMP1 ribonucleoprotein granules.	IGF2BP1 IGF2BP3 IGF2BP2	8.53e-05	36	82	3	17289661
Pubmed	Identification of Human Neuronal Protein Complexes Reveals Biochemical Activities and Convergent Mechanisms of Action in Autism Spectrum Disorders.	IGF2BP1 IGF2BP3 SYNE2 GLCCI1	9.85e-05	101	82	4	26949739
Pubmed	Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	PDS5B SLC9A8 SYNE2 WDR37	1.02e-04	102	82	4	10231032
Pubmed	A fast Myosin super enhancer dictates muscle fiber phenotype through competitive interactions with Myosin genes.	MYH2 MYH8	1.14e-04	7	82	2	35210422
Pubmed	Association of six single nucleotide polymorphisms with gestational diabetes mellitus in a Chinese population.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	22096510
Pubmed	Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	18618095
Pubmed	Type 2 diabetes risk alleles are associated with reduced size at birth.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	19228808
Pubmed	Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	19008344
Pubmed	Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	18162508
Pubmed	Diversity in transcriptional start site selection and alternative splicing affects the 5'-UTR of mouse striated muscle myosin transcripts.	MYH2 MYH8	1.14e-04	7	82	2	16819597
Pubmed	Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population.	IGF2BP2 CDKAL1	1.14e-04	7	82	2	17928989
Pubmed	Protein interaction studies in human induced neurons indicate convergent biology underlying autism spectrum disorders.	IGF2BP1 IGF2BP3 IGF2BP2	1.46e-04	43	82	3	36950384
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	PDS5B IGF2BP1 IGF2BP3 IGF2BP2 SACS SUPT5H SYNE2 PACSIN3 UTRN RAD50	1.47e-04	1024	82	10	24711643
Pubmed	Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	18469204
Pubmed	Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	20043145
Pubmed	Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	17804762
Pubmed	Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	19033397
Pubmed	Genetic variant in the IGF2BP2 gene may interact with fetal malnutrition to affect glucose metabolism.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	19258437
Pubmed	Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	18544707
Pubmed	MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology.	MFN2 UTRN	1.52e-04	8	82	2	16936636
Pubmed	The longitudinal association of common susceptibility variants for type 2 diabetes and obesity with fasting glucose level and BMI.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	20929593
Pubmed	Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	20424228
Pubmed	Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population.	IGF2BP2 CDKAL1	1.52e-04	8	82	2	18633108
Pubmed	Mouse HORMAD1 is a meiosis i checkpoint protein that modulates DNA double- strand break repair during female meiosis.	SYCP2 HORMAD1	1.52e-04	8	82	2	23759310
Pubmed	Proteome analysis of the HIV-1 Gag interactome.	IGF2BP1 IGF2BP3 IGF2BP2	1.56e-04	44	82	3	25010285
Pubmed	Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs.	IGF2BP1 IGF2BP3 IGF2BP2	1.67e-04	45	82	3	23663784
Pubmed	Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells.	IGF2BP1 IGF2BP3 IGF2BP2 TOPAZ1	1.68e-04	116	82	4	21282530
Pubmed	HOXA5 plays tissue-specific roles in the developing respiratory system.	MYH2 MYH8 FSTL1	1.78e-04	46	82	3	28827394
Pubmed	Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.	PDS5B NCAPD3 SUPT5H TRIM24 RAD50	1.85e-04	222	82	5	37071664
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	INTU SLC9A8 COQ8A RPS6KB1 TP53I11 KNDC1 PRPF38B WDR37 UTRN VPS13B DNAH14 MAPK8IP3	1.88e-04	1489	82	12	28611215
Pubmed	Discovering human diabetes-risk gene function with genetics and physiological assays.	IGF2BP2 GLIS3	1.96e-04	9	82	2	30242153
Pubmed	Association study of genetic variants in eight genes/loci with type 2 diabetes in a Han Chinese population.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	20550665
Pubmed	Contribution of common genetic variation to the risk of type 2 diabetes in the Mexican Mestizo population.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	22923468
Pubmed	Polymorphisms identified through genome-wide association studies and their associations with type 2 diabetes in Chinese, Malays, and Asian-Indians in Singapore.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	19892838
Pubmed	The inhibitory effect of recent type 2 diabetes risk loci on insulin secretion is modulated by insulin sensitivity.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	19258404
Pubmed	Beta cell glucose sensitivity is decreased by 39% in non-diabetic individuals carrying multiple diabetes-risk alleles compared with those with no risk alleles.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	18719881
Pubmed	Transdifferentiation of esophageal smooth to skeletal muscle is myogenic bHLH factor-dependent.	MYH2 MYH8	1.96e-04	9	82	2	10725239
Pubmed	Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population.	IGF2BP2 CDKAL1	1.96e-04	9	82	2	18991055
Pubmed	Six1 homeoprotein drives myofiber type IIA specialization in soleus muscle.	MYH2 MYH8 TNNT3	2.29e-04	50	82	3	27597886
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	IGF2BP1 IGF2BP3 FAM186A VPS13B RAD50	2.36e-04	234	82	5	36243803
Pubmed	Age-associated alteration of gene expression patterns in mouse oocytes.	CGGBP1 TOPORS TRIM24	2.42e-04	51	82	3	15317747
Cytoband	15q25.2	GOLGA6L10 GOLGA6L9 GOLGA6L4	6.21e-05	43	81	3	15q25.2
GeneFamily	Myosin heavy chains	MYH2 MYH8	5.17e-04	15	41	2	1098
GeneFamily	Rho GTPase activating proteins\|F-BAR domain containing	SRGAP3 PACSIN3	1.23e-03	23	41	2	1288
GeneFamily	RNA binding motif containing	IGF2BP1 IGF2BP3 IGF2BP2	1.24e-02	213	41	3	725
GeneFamily	WD repeat domain containing	PIK3R4 CFAP43 WDR37	2.14e-02	262	41	3	362
Coexpression	CARRILLOREIXACH_HEPATOBLASTOMA_VS_NORMAL_HYPOMETHYLATED_AND_UP	IGF2BP1 IGF2BP2 PLXNC1 DLGAP5 MTBP PARPBP	1.05e-05	162	80	6	M45037
Coexpression	HE_LIM_SUN_FETAL_LUNG_C5_PRO_B_CELL	PDS5B NCAPD3 IGF2BP2 SYNE2 DLGAP5 FEN1 PARPBP TRIM24 RAD54L	1.52e-05	478	80	9	M45785
Coexpression	MEK_UP.V1_UP	ABCC3 RFTN1 IGF2BP2 TP53I11 PACSIN3 TNFRSF11B	2.99e-05	195	80	6	M2725
Coexpression	HUMMERICH_BENIGN_SKIN_TUMOR_DN	MYH2 MYH8 TNNT3	3.01e-05	20	80	3	M1123
Coexpression	HUMMERICH_MALIGNANT_SKIN_TUMOR_DN	MYH2 MYH8 TNNT3	3.01e-05	20	80	3	M1127
Coexpression	HAMAI_APOPTOSIS_VIA_TRAIL_UP	PDS5B FSTL1 SACS PLXNC1 SYNE2 DLGAP5 PRPF38B PARPBP TRIM24 RAD50	3.07e-05	656	80	10	M18979
Coexpression	GSE22935_WT_VS_MYD88_KO_MACROPHAGE_48H_MBOVIS_BCG_STIM_UP	MLXIPL PACSIN3 MFN2 UTRN CDKAL1 TNFRSF11B	3.35e-05	199	80	6	M7766
Coexpression	GSE10239_KLRG1INT_VS_KLRG1HIGH_EFF_CD8_TCELL_DN	RTF1 PLXNC1 DLGAP5 RELL1 CGGBP1 VPS13B	3.35e-05	199	80	6	M3070
Coexpression	HUMMERICH_MALIGNANT_SKIN_TUMOR_DN	MYH2 MYH8 TNNT3	3.50e-05	21	80	3	MM1103
Coexpression	HUMMERICH_BENIGN_SKIN_TUMOR_DN	MYH2 MYH8 TNNT3	3.50e-05	21	80	3	MM1102
Coexpression	RATTENBACHER_BOUND_BY_CELF1	SRGAP3 SOCS4 PRPF38B SEL1L2 PARPBP GLCCI1 ADAM28 CAVIN2	6.36e-05	444	80	8	M2505
Coexpression	CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	RFTN1 IGF2BP3 IGF2BP2 FSTL1 SACS GLIS3 ADAMTS5 CAVIN2	8.76e-05	465	80	8	M9192
Coexpression	LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP	IGF2BP3 IGF2BP2 HORMAD1 TNFRSF11B	1.23e-04	83	80	4	M15975
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN	PDS5B WDR37 TRIM24 VPS13B	1.29e-04	84	80	4	M13008
CoexpressionAtlas	DevelopingKidney_e15.5_Peripheral blastema_emap-27731_k-means-cluster#5_top-relative-expression-ranked_1000	PDS5B FSTL1 RPS6KB1 SOCS4 PARPBP	1.14e-05	79	79	5	gudmap_developingKidney_e15.5_Peripheral blastema_1000_k5
CoexpressionAtlas	facebase_RNAseq_e10.5_Emin_LatNas_2500_K3	CCDC88C IGF2BP1 IGF2BP3 TMA16 NKAPD1 RPS6KB1 SYNE2 RIBC1 MTBP PRPF38B TOPORS PARPBP TRIM24 CDKAL1 RAD54L RAD50	1.29e-05	1257	79	16	facebase_RNAseq_e10.5_Emin_LatNas_2500_K3
CoexpressionAtlas	Fetal Liver, SC.STSL.FL, IgM- CD24- CD117+ IL7R- CD150- CD48- AA4.1+ CD43+, Fetal Liver, avg-2	IGF2BP1 IGF2BP3 IGF2BP2 FSTL1 PLXNC1 SYNE2 DLGAP5 PARPBP RAD54L	2.13e-05	410	79	9	GSM791122_500
CoexpressionAtlas	FacebaseRNAseq_e9.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#2	RTF1 PIK3R4 PDS5B NKAPD1 RPS6KB1 PRPF38B PARPBP TRIM24 UTRN RAD50	4.49e-05	564	79	10	Facebase_RNAseq_e9.5_Mandibular Arch_2500_K2
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_2500_k-means-cluster#4	PDS5B PLXNC1 RPS6KB1 SYNE2 DLGAP5 MFN2 PRPF38B PARPBP TRIM24 RAD50	7.01e-05	595	79	10	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_2500_K4
CoexpressionAtlas	facebase_RNAseq_e10.5_Emin_LatNas_2500	CCDC88C IGF2BP1 IGF2BP3 TMA16 NKAPD1 RPS6KB1 SYNE2 RIBC1 MTBP PRPF38B TOPORS PARPBP TRIM24 CDKAL1 RAD54L RAD50	7.88e-05	1459	79	16	facebase_RNAseq_e10.5_Emin_LatNas_2500
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC3 SRGAP3 SYNE2 GLIS3 CFAP43 DNAH14 TNFRSF11B	6.47e-08	191	82	7	d0e9afe7b6334dd515d3e68892efdc76347a55e5
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_A2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MLXIPL IGF2BP2 DLGAP5 TNNT3 GOLGA6L4 CAVIN2	5.35e-07	161	82	6	8ec923c230a7a3cce5edf2a736b3a00d607c698a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SRGAP3 GLIS3 UTRN GLCCI1 DNAH14 CDKAL1	1.32e-06	188	82	6	63a4b25a0a6e05f80f1a6dd91b817f3cf49e6b68
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SRGAP3 SYNE2 CFAP43 DNAH14 CDKAL1 TNFRSF11B	1.36e-06	189	82	6	904b8337e2cabac2f0bf5dad5598fc429581ed81
ToppCell	NS-moderate-d_16-33-Epithelial-FOXN4+\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CCDC14 INTU SYCP2 DLGAP5 FAM227A RAD54L	1.41e-06	190	82	6	250ca4a605c1cccd77d23383e4fe6f91cf3609ba
ToppCell	human_hepatoblastoma-Tumor_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	MLXIPL IGF2BP1 IGF2BP3 IGF2BP2 TRIM24 DNAH14	1.54e-06	193	82	6	503a979328c68b096680b71359a26f02fafdff35
ToppCell	moderate-Epithelial-FOXN4+\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CCDC14 SYCP2 CEP95 DLGAP5 FAM227A UTRN	1.59e-06	194	82	6	dff3fb10372053951d41e0ccd41aac3ece6009bd
ToppCell	proximal-Hematologic-Proliferating_Macrophage\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 GRIN3A PARPBP RAD54L	1.73e-06	197	82	6	0b1fa881abbfcc54b322fc27124db3f8947af016
ToppCell	proximal-3-Hematologic-Proliferating_Macrophage\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 GRIN3A PARPBP RAD54L	1.73e-06	197	82	6	0dd9058aa19d1268ebba9a65555870224b5a5978
ToppCell	proximal-Hematologic-Proliferating_Macrophage-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 GRIN3A PARPBP RAD54L	1.73e-06	197	82	6	9243617b307acf3df40d93c41cd8d4788699a7ea
ToppCell	(11)_FOXN4+-(2)_GFP_FOXI1\|(11)_FOXN4+ / shred by cell type by condition	RTF1 SYNE2 PRPF38B TRIM24 UTRN RAD50	1.79e-06	198	82	6	76d40b8c2f8399725b3a62ee2ae0896559cf91eb
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-FOXM1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CCDC14 NCAPD3 SYNE2 DLGAP5 PARPBP RAD54L	1.84e-06	199	82	6	98575fcce726589e93fbb4df1aab03e57cb56076
ToppCell	droplet-Lung-nan-3m-Lymphocytic-Proliferating_NK\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CCDC14 DLGAP5 MTBP PARPBP RAD54L	1.10e-05	158	82	5	ee8ce3cd202807df692b28bb1a81827d49d73862
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l44-58\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MYH8 PARPBP TNNT3 TNMD HORMAD1	1.44e-05	167	82	5	d78356bf0c473816dbabaee51984940bd822f84e
ToppCell	Sigmoid-Macrophage-Macrophage\|Macrophage / Region, Cell class and subclass	PLXNC1 SRGAP3 PRPF38B UTRN ADAM28	1.48e-05	168	82	5	bb16e135b6ae0d66615420b61edd6f62f2a3233c
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 SACS DLGAP5 MTBP PARPBP	1.70e-05	173	82	5	20889aa85e36ad3bafdb91b91e43964493c949f9
ToppCell	368C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 SACS DLGAP5 MTBP PARPBP	1.70e-05	173	82	5	46e601b7938b1dd0aa3df7aa056c4bd07b1620c1
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue-Breast_normal_tissue-3\|TCGA-Breast / Sample_Type by Project: Shred V9	ADRA1A ADAMTS5 TNMD NKAPL CAVIN2	1.75e-05	174	82	5	7f8f5fafae08676d2b90cab9802c3c9320f1370e
ToppCell	TCGA-Breast-Solid_Tissue_Normal\|TCGA-Breast / Sample_Type by Project: Shred V9	ADRA1A ADAMTS5 TNMD NKAPL CAVIN2	1.75e-05	174	82	5	e2f240d60bffbe8e6d60f0bb405b231bd3c96875
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue-Breast_normal_tissue\|TCGA-Breast / Sample_Type by Project: Shred V9	ADRA1A ADAMTS5 TNMD NKAPL CAVIN2	1.75e-05	174	82	5	0f3ec0d0d4344e10c9b48adc9174123f6402dc51
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Myeloid-Lymphoid_DC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RFTN1 DSC3 IGHE PLXNC1 TNFRSF11B	1.75e-05	174	82	5	16204ff504b7b382b4d90ca35003ad5336020e07
ToppCell	TCGA-Breast-Solid_Tissue_Normal-Breast_normal_tissue\|TCGA-Breast / Sample_Type by Project: Shred V9	ADRA1A ADAMTS5 TNMD NKAPL CAVIN2	1.75e-05	174	82	5	1aadbf2642b6d1320ceabd92e6ff59e11f16c315
ToppCell	droplet-Heart-nan-3m-Endothelial-coronary_vascular_endothelial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CCDC88C SACS SYNE2 UTRN CAVIN2	2.12e-05	181	82	5	92d44892bb15771f0ab5fe61879b204b0acbd9b3
ToppCell	3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NCAPD3 DLGAP5 FEN1 RAD54L AGBL3	2.12e-05	181	82	5	e4dbc09f0210de465d8347969b301c22463a2b7d
ToppCell	droplet-Heart-nan-3m-Endothelial-endothelial_cell_of_coronary_artery\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CCDC88C SACS SYNE2 UTRN CAVIN2	2.17e-05	182	82	5	81279877b920b5a1bc991a07d3031d6458700fe3
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-5\|TCGA-Liver / Sample_Type by Project: Shred V9	IGF2BP3 DLGAP5 MTBP PARPBP RAD54L	2.23e-05	183	82	5	f604a8b62c7088fad8365dbf8d910fc980bd3ba8
ToppCell	COVID-19-kidney-PCT-S1\|kidney / Disease (COVID-19 only), tissue and cell type	ABCC3 MLXIPL SYNE2 GLIS3 AGBL3	2.29e-05	184	82	5	51ed1ebfdef45149541917c66cbacad87072e51f
ToppCell	Ciliated_cells-A-Donor_04\|World / lung cells shred on cell class, cell subclass, sample id	SRGAP3 RIBC1 FAM227A CFAP43 GOLGA6L9	2.35e-05	185	82	5	d77ca57b02125a3a57a37f4aed20c89803b7d551
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-Undetermined\|Fibroblasts / Location, Cell class and cell subclass	ABCC3 PLXNC1 CEP95 PRPF38B WDR37	2.41e-05	186	82	5	403ac98f72a42721f84fbd7826f251a88ae534a2
ToppCell	COVID-19-lung-Plasma_cells_PRDM1/BLIMP_hi\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CCDC88C DLGAP5 PARPBP GLCCI1 ADAM28	2.54e-05	188	82	5	567b08514d9d84cbb40f9b7a679eec304f023428
ToppCell	pdx-Tumor_cells-T1\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	PDS5B NCAPD3 DLGAP5 PARPBP RAD54L	2.67e-05	190	82	5	d06ee5f89f1cec8db6897fe3b2a890a07cd3697b
ToppCell	Mild-T/NK_proliferative\|World / Disease group and Cell class	NCAPD3 SYCP2 DLGAP5 FEN1 RAD54L	2.74e-05	191	82	5	9dba5526fd5ea8065ad305feb2ee562335f887c6
ToppCell	NS-moderate-d_0-4\|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	INTU SRGAP3 GLIS3 FAM227A CFAP43	2.88e-05	193	82	5	ea345d34440b25f65358a53dc72831998d1c3620
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_cycling-mes_proliferating3_(7)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	2.95e-05	194	82	5	f9070035553bc68106a9e0bdf4b507715a138aba
ToppCell	COVID-19_Severe-Non-classical_Monocyte-\|COVID-19_Severe / Disease condition and Cell class	CCDC88C ABCC3 RFTN1 KNDC1 UTRN	2.95e-05	194	82	5	d70b9039fd2fef3e4be086513b94fb7e9bc1f670
ToppCell	367C-Myeloid-Macrophage-FABP4+_Macrophage_proliferating\|367C / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	2.95e-05	194	82	5	a12b64945e10f00aa983678a02586c59badc1570
ToppCell	COVID-19_Severe-Non-classical_Monocyte\|COVID-19_Severe / Disease condition and Cell class	CCDC88C ABCC3 RFTN1 KNDC1 UTRN	2.95e-05	194	82	5	5151546812678ae85cb22224084d27b29e3c4724
ToppCell	367C-Myeloid-Macrophage-FABP4+_Macrophage_proliferating\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.10e-05	196	82	5	9591a6a3477ed6a1e2e016f7542e38603d8b16cb
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_cycling-mes_proliferating3_(7)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.10e-05	196	82	5	1964c5003a0cb84539850a7cfe3bbb0e23a61d2d
ToppCell	356C-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.10e-05	196	82	5	34bd155e6d848eb53d613997c0e244535de30ba3
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_cycling-mes_proliferating3_(7)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.18e-05	197	82	5	84ed777cdba569200a3ef1654d8a12f17fcfb7f1
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	INTU IGF2BP2 SYNE2 FAM227A CFAP43	3.18e-05	197	82	5	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.2.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.18e-05	197	82	5	7eb4c1cffd0366204af7e63adc8f751685601a94
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_airway_basal-Suprabasal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SYCP2 DSC3 SRGAP3 TNNT3 ADAM28	3.25e-05	198	82	5	28ada093cec552262731194a04a4b9ff93186c3b
ToppCell	COVID-19_Moderate-T/NK_proliferative\|World / disease group, cell group and cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	bf0131fbca6032e1aab4aa807f8c1d3be689cb7f
ToppCell	356C-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2\|Macrophage / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	6a10bb81817ab606f1f5a2bd8cfe77ef2fb3f2fb
ToppCell	distal-1-Hematologic-Proliferating_Macrophage\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	df3f5559ecd1f3cd1fd60e39dbad8741309e83a3
ToppCell	distal-Hematologic-Proliferating_Macrophage-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	8afeb1f9bc9d8551482c8fefe4c5f88d9cd13ee2
ToppCell	distal-Hematologic-Proliferating_Macrophage-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	2b0716e900bce54ad1825d6dcdaf4ebf31f355c4
ToppCell	COVID-19_Severe-T/NK_proliferative\|World / disease group, cell group and cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.25e-05	198	82	5	48045689d0969ff0a14eee7086b8e19b0d6b6065
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-T/NK_proliferative-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	11c3d9fe811a4619347f47d2b0e94066e3085625
ToppCell	severe_influenza-T/NK_proliferative\|severe_influenza / disease group, cell group and cell class (v2)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	638b1491c47f2884daf1c1d38a779ad8e0f59c52
ToppCell	VE-cycling\|VE / Condition, Cell_class and T cell subcluster	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	47c47ebc318a0b98841ca2656837bbd068899559
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-T/NK_proliferative-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	36c80907b2ec1cbcd1b4e841e6c02a4792591d74
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-T/NK_proliferative\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	bf4c31902ae8358215245a2e11b5a2fe4ca1bc8c
ToppCell	severe_influenza-T/NK_proliferative\|World / disease group, cell group and cell class (v2)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	1541f655f7d12c650added3683d07e5417a68dfb
ToppCell	COVID-19_Mild-Lymphoid_T/NK-T/NK_proliferative\|COVID-19_Mild / Disease group, lineage and cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	ddea0e5c1cb6a096ab8e09a8c3c37c1bff381d9c
ToppCell	(02)_MMP9/10+-(2)_GFP_FOXI1\|(02)_MMP9/10+ / shred by cell type by condition	RTF1 SYNE2 ADAMTS5 GLCCI1 RAD50	3.33e-05	199	82	5	18a7f9ced4364f45b184bd529f32ef02c27779d3
ToppCell	PBMC-Mild-Lymphocyte-T/NK-Other_T-T/NK_proliferative\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	7beb0e07a27fea94674f24eb61c381b0de38ed3e
ToppCell	COVID-19-Lymphoid-Proliferating_CD4_T_cells\|COVID-19 / Condition, Lineage and Cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	e1dfc856a85a91e8f7ab8d600a8a891d16b2aefb
ToppCell	367C-Myeloid-Macrophage-FABP4+_Macrophage_proliferating\|Macrophage / Donor, Lineage, Cell class and subclass (all cells)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	88d130e2451e61afb710edf552e6b346b9fcfb2b
ToppCell	VE-cycling-\|VE / Condition, Cell_class and T cell subcluster	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.33e-05	199	82	5	c0a67149a19b65b3069dbc5261d81f658e6e39a2
ToppCell	LPS_IL1RA-Endothelial-Endothelial-FOXM1\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	NCAPD3 SYNE2 DLGAP5 PARPBP RAD54L	3.33e-05	199	82	5	be2276c9a1994579ba1d2998b49bf549c1324d44
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-FOXM1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	CCDC14 NCAPD3 DLGAP5 PARPBP RAD54L	3.41e-05	200	82	5	4cfe08878a6981bf7b3567f9e82192d8f060ddde
ToppCell	distal-Hematologic-Proliferating_Macrophage\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	3835a8a9739b8cd5bf19c40765ef76907ac1ad38
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW08-Stem_cells\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	CCDC88C FSTL1 SOCS4 DLGAP5 RAD54L	3.41e-05	200	82	5	691b3edf7d8449556e8bf611662eb85772959f0f
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-T/NK_proliferative\|COVID-19_Mild / Disease, condition lineage and cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	6126a3bbafe2110fba0c1c4493035df4e8193d22
ToppCell	BAL-Severe-Lymphocyte-T/NK-Other_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	535f6fba8d03873ba35c9949579161dc41cd7a60
ToppCell	Severe_COVID-19-T/NK-proliferating_T/NK\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	52265e761a961f3724b388285e0919bd58847138
ToppCell	healthy_donor-Lymphocytic-Proliferative_Lymphocyte\|healthy_donor / Disease condition, Lineage, Cell class and subclass	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	e4eb915c29909cf8535a3603c68976545c05e54b
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW08-Stem_cells-Stem_cells\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	CCDC88C FSTL1 SOCS4 DLGAP5 RAD54L	3.41e-05	200	82	5	36a110aa91a791fdf1142e7869e8aa0d342402d0
ToppCell	healthy_donor-Lymphocytic-Proliferative_Lymphocyte-\|healthy_donor / Disease condition, Lineage, Cell class and subclass	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	415e7556b5ac45688e2c6c30a52bd40e0eb27c7d
ToppCell	BAL-Severe-Lymphocyte-T/NK-Other_T-T/NK_proliferative\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	60d11275f06490f86f400a2802492f9c1b570400
ToppCell	distal-Hematologic-Proliferating_Macrophage-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	9c03a8da12d29618f72c429836c1d1bd84a78b12
ToppCell	COVID_non-vent-Lymphocytic-Proliferative_Lymphocyte-\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	04bf9e6a0fbd792b49eed63dabba5d6fafed8c07
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW08-Stem_cells-Neuroepithelial_cell\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	CCDC88C FSTL1 SOCS4 DLGAP5 RAD54L	3.41e-05	200	82	5	4e077aa7faddcebdfc54667f8b3990704441005b
ToppCell	Sepsis-URO-Lymphocyte-T/NK-T/NK_proliferative\|URO / Disease, condition lineage and cell class	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	f277db6cc288a52a5426120c1067608700ee8ccc
ToppCell	Biopsy_Other_PF-Immune-Proliferating_Macrophages\|Biopsy_Other_PF / Sample group, Lineage and Cell type	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	61473e8613f39a92002d5b631e6bd563735566e4
ToppCell	BL-critical-LOC-Lymphoid-Treg\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	04d95a9102248e98eed069840ea6d3d23a243fd5
ToppCell	BAL-Severe-Lymphocyte-T/NK-Other_T-T/NK_proliferative-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	0e44a55d65b72eb40543d3bde301f8598ac251c3
ToppCell	COVID_non-vent-Lymphocytic-Proliferative_Lymphocyte\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	f6b5320cdfe640a71e6e2df26f30d42e64b1c921
ToppCell	distal-3-Hematologic-Proliferating_Macrophage\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NCAPD3 DLGAP5 FEN1 PARPBP RAD54L	3.41e-05	200	82	5	1b65c97e8123d0572d31525d6a10bc7f16857959
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW08-Stem_cells\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	CCDC88C FSTL1 SOCS4 DLGAP5 RAD54L	3.41e-05	200	82	5	d17ba4239e1fd702a3d757687110f0f2c6f91ef7
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_activated\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MYH8 ADRA1A SYNE2 RIBC1	6.71e-05	118	82	4	5f72022f4be3fb7ccec86dc05d37572833028886
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_activated-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MYH8 ADRA1A SYNE2 RIBC1	6.71e-05	118	82	4	053c0986051e36fdc4c48b8067c137b6299b2f1b
ToppCell	Control-Lymphoid_T/NK-NK_activated\|Control / Disease group, lineage and cell class	MYH8 ADRA1A SYNE2 RIBC1	6.94e-05	119	82	4	a258d91ac90d4174b6f203d7f96ba6e57c6003e7
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_activated\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MYH8 ADRA1A SYNE2 RIBC1	6.94e-05	119	82	4	28d6b0e9dda2fe4ca94ae9b95b7261618d0d9877
ToppCell	Control-NK_activated\|Control / Disease condition and Cell class	MYH8 ADRA1A RIBC1 GRIN3A	6.94e-05	119	82	4	0d0bab03d56e269c6e637b0bbeffe9d1491dfc33
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell-NK_activated-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MYH8 ADRA1A SYNE2 RIBC1	6.94e-05	119	82	4	0fdd5b093ac20a4bda0f7b623808eb3ad0bf68e2
ToppCell	(08)_Brush+PNEC-(2)_GFP_FOXI1\|(08)_Brush+PNEC / shred by cell type by condition	RTF1 SYNE2 CAVIN2 RAD50	1.23e-04	138	82	4	817e3f639604ea95adae01e8685ffaa2e0aff7a8
ToppCell	Substantia_nigra-Hematopoietic-MICROGLIA\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	ABCC3 MLXIPL DLGAP5 PARPBP	1.70e-04	150	82	4	d44c02402e59a45e40b8fffbe71284032b5e7c92
ToppCell	Substantia_nigra-Hematopoietic-MICROGLIA-MI2(C1qb)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	ABCC3 MLXIPL DLGAP5 PARPBP	1.70e-04	150	82	4	e020dbcf85c0ba7ad667b8bbeb6bbcfc135c9bb7
ToppCell	Substantia_nigra-Hematopoietic-MICROGLIA-MI2(C1qb)-MICROGLIA_Microglia.C1qb.Tmem119_(Microglia.C1qb.Tmem119)-\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	ABCC3 MLXIPL DLGAP5 PARPBP	1.70e-04	150	82	4	edbc1d29d213bf5908592135700e0d80e123c923
ToppCell	Substantia_nigra-Hematopoietic-MICROGLIA-MI2(C1qb)-MICROGLIA_Microglia.C1qb.Tmem119_(Microglia.C1qb.Tmem119)--\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	ABCC3 MLXIPL DLGAP5 PARPBP	1.70e-04	150	82	4	01c526e1e3007e71e416c317549fddd2919b14e9
ToppCell	Substantia_nigra-Hematopoietic-MICROGLIA-MI2(C1qb)-MICROGLIA_Microglia.C1qb.Tmem119_(Microglia.C1qb.Tmem119)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	ABCC3 MLXIPL DLGAP5 PARPBP	1.70e-04	150	82	4	b7f5bf9af7ed50aad4da1c71d37b8b9709e6ce85
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_A2\|356C / Donor, Lineage, Cell class and subclass (all cells)	MLXIPL DLGAP5 TNNT3 GOLGA6L4	1.70e-04	150	82	4	6bdf9df586f348641a25a445e83a41e47e7f347e
ToppCell	BAL-Control-cDC_12\|Control / Compartment, Disease Groups and Clusters	MLXIPL FAM227A DNAH14 RAD54L	1.88e-04	154	82	4	0121d08cc527aed9b3e11ff62bb9012916f5c56b
ToppCell	TCGA-Thymus-Primary_Tumor-Thymoma-Type_C-8\|TCGA-Thymus / Sample_Type by Project: Shred V9	IGF2BP3 IGHE GLIS3 TNFRSF11B	1.92e-04	155	82	4	00eef9f93a753a1fe1ab5fd8dae026e7be556cde
ToppCell	10x5'-Liver-Myeloid_Mac-Intestinal_macrophages\|Liver / Manually curated celltypes from each tissue	ABCC3 INTU SRGAP3 KNDC1	1.97e-04	156	82	4	9a897fc79c4fae94c5f2e9012d65297f9225e5e3
ToppCell	NS-moderate-d_07-13-Epithelial-FOXN4+\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	INTU DLGAP5 FAM227A RAD54L	2.02e-04	157	82	4	410c9d74a2085179cfb39853cb6d330fa98c9c1b
Disease	acquired metabolic disease (implicated_via_orthology)	IGF2BP1 IGF2BP3 IGF2BP2	6.82e-08	4	77	3	DOID:0060158 (implicated_via_orthology)
Disease	disease of cellular proliferation (is_implicated_in)	MYH8 RAD54L	2.01e-05	3	77	2	DOID:14566 (is_implicated_in)
Disease	Liver carcinoma	MLXIPL IGF2BP1 IGF2BP3 ADRA1A DLGAP5 MTBP TRIM24 RAD54L	5.35e-05	507	77	8	C2239176
Disease	Distal arthrogryposis	MYH8 TNNT3	2.39e-04	9	77	2	cv:C0265213
Disease	dilated cardiomyopathy 1S (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0110454 (implicated_via_orthology)
Disease	autosomal dominant hyaline body myopathy (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0111269 (implicated_via_orthology)
Disease	congenital myopathy 6 (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0080719 (implicated_via_orthology)
Disease	distal arthrogryposis type 2B3 (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0111602 (implicated_via_orthology)
Disease	inclusion body myositis (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:3429 (implicated_via_orthology)
Disease	Abnormality of nervous system morphology	WDR37 MAPK8IP3	2.98e-04	10	77	2	C4022810
Disease	distal arthrogryposis type 2A (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0111605 (implicated_via_orthology)
Disease	familial hypertrophic cardiomyopathy (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0080326 (implicated_via_orthology)
Disease	distal arthrogryposis type 1 (implicated_via_orthology)	MYH2 MYH8	2.98e-04	10	77	2	DOID:0111596 (implicated_via_orthology)
Disease	acute insulin response measurement	IGF2BP2 CDKAL1	3.64e-04	11	77	2	EFO_0006831
Disease	distal myopathy (implicated_via_orthology)	MYH2 MYH8	4.36e-04	12	77	2	DOID:11720 (implicated_via_orthology)
Disease	myotonia congenita (implicated_via_orthology)	MYH2 MYH8	4.36e-04	12	77	2	DOID:2106 (implicated_via_orthology)
Disease	peak insulin response measurement	IGF2BP2 CDKAL1	5.15e-04	13	77	2	EFO_0008000
Disease	restrictive cardiomyopathy (implicated_via_orthology)	MYH2 MYH8	5.15e-04	13	77	2	DOID:397 (implicated_via_orthology)
Disease	non-alcoholic fatty liver disease (biomarker_via_orthology)	ABCC3 MLXIPL MFN2	6.64e-04	65	77	3	DOID:0080208 (biomarker_via_orthology)
Disease	infant head circumference	IGF2BP3 CDKAL1	6.90e-04	15	77	2	EFO_0004577
Disease	distal arthrogryposis (implicated_via_orthology)	MYH2 MYH8	6.90e-04	15	77	2	DOID:0050646 (implicated_via_orthology)
Disease	asthma	RTF1 PDS5B PLXNC1 SRGAP3 GLIS3 TNFRSF11B SENP7 RAD50	7.60e-04	751	77	8	MONDO_0004979
Disease	cardiomyopathy (implicated_via_orthology)	MYH2 MYH8 TNNT3	8.60e-04	71	77	3	DOID:0050700 (implicated_via_orthology)
Disease	number of teeth measurement	IGF2BP1 IGF2BP3	1.24e-03	20	77	2	EFO_0010073
Disease	Left Ventricle Remodeling	ADRA1A MFN2	1.37e-03	21	77	2	C0600520
Disease	Ventricular Remodeling	ADRA1A MFN2	1.37e-03	21	77	2	C0600519
Disease	gestational diabetes	IGF2BP2 CDKAL1	1.64e-03	23	77	2	EFO_0004593
Disease	body fat percentage, coronary artery disease	IGF2BP1 HORMAD1	1.79e-03	24	77	2	EFO_0001645, EFO_0007800
Disease	HbA1c measurement	MLXIPL IGF2BP3 IGF2BP2 FAM186A RPS6KB1 GLIS3 CDKAL1	1.91e-03	675	77	7	EFO_0004541
Disease	glutamine measurement	MLXIPL GLIS3 CDKAL1	2.11e-03	97	77	3	EFO_0009768
Disease	mean corpuscular hemoglobin concentration	PDS5B MYH2 MLXIPL INTU FAM227A CGGBP1 VPS13B CDKAL1 SENP7	2.31e-03	1105	77	9	EFO_0004528
Disease	neutrophil count, eosinophil count	RTF1 COQ8A GLCCI1 CDKAL1	2.37e-03	213	77	4	EFO_0004833, EFO_0004842
Disease	hemoglobin A1 measurement	MLXIPL IGF2BP3 IGF2BP2 SRGAP3 SYNE2 CDKAL1	2.40e-03	520	77	6	EFO_0007629
Disease	osteoarthritis (is_implicated_in)	ADAMTS5 TNFRSF11B	2.43e-03	28	77	2	DOID:8398 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
HARSSVIKRKTADKN	FAM227A	116	F5H4B4
KTKKERNSTIASHQN	AGBL3	641	Q8NEM8
RKQHEKSQTSEAVRK	CFAP43	1251	Q8NDM7
IRHQSSREKQKKDQR	ADAM28	686	Q9UKQ2
THIKVRQFKAKDQTR	ADAMTS5	756	Q9UNA0
KSDSEQVTLRIHRKN	ADRA1A	226	P35348
LQRSKQSSRHSKEKD	GLCCI1	241	Q86VQ1
THTKRKAEFEEQNVR	CGGBP1	66	Q9UFW8
NIHVRDTKTVKDVQK	CCDC14	406	Q49A88
NTEQKSKSKQHRVSR	PDS5B	1336	Q9NTI5
KKHSQTDLVSRLKTR	TP53I11	11	O14683
ADKDEQIRKIKSRHS	RAD50	546	Q92878
HSKSKEINQTRDRLA	RAD50	581	Q92878
TIEEKIFQRQSHKKA	RAD54L	626	Q92698
IKKTDRSQKTDLHNE	RFTN1	106	Q14699
HLDRSKNEKVSRKST	PARPBP	486	Q9NWS1
RKQEKQTARHKASAA	ABCC3	261	O15438
RKTQHKRTQVDDVDC	ANKRD31	731	Q8N7Z5
DSHKKTSVLRKVQQC	OTOA	671	Q7RTW8
KQEQTHSKASRRQEI	nan	326	O00370
RASREHPSVQEKKKS	MAPK8IP3	556	Q9UPT6
ITKQTQSKIDVHRKE	IGF2BP1	221	Q9NZI8
KDNRDLTKQVTVHAR	CCDC88C	891	Q9P219
NKLRVKSREVHTKIS	MYH8	1921	P13535
TRHKSKELSRKQSQQ	PLXNC1	966	O60486
SQVNKLRVKSREVHT	MYH2	1921	Q9UKX2
VRNAKDTAHTKAERN	RPS6KB1	131	P23443
NINSLVRTSKEEKKH	GOLGA6L3	111	A6NEY3
NINSLVRTSKEEKKH	GOLGA6L4	111	A6NEF3
NINSLVRTSKEEKKH	GOLGA6L9	111	A6NEM1
NINSLVRTSKEEKKH	GOLGA6L10	111	A6NI86
NINSLVRTSKEEKKH	GOLGA6L19	111	H0YKK7
KQTQSRVDIHRKENS	IGF2BP2	221	Q9Y6M1
ITKQTQSKIDVHRKE	IGF2BP3	221	O00425
SRCNSIVTVKKNKRH	MFN2	6	O95140
KQQHFKTKRVEKRSN	GRIN3A	991	Q8TCU5
DVKRETSHPRQKKTQ	INTU	266	Q9ULD6
FTKRLVKVTKQHNDE	FEN1	126	P39748
QKKVSKTRHTRETVL	DSC3	116	Q14574
QVKKQRTKDLSRVFH	CDKAL1	411	Q5VV42
QKHQETAEKTKRVST	FSTL1	291	Q12841
HSSKEQQARKKLRSS	GLIS3	496	Q8NEA6
KQHKQTLSEHARERK	COQ8A	191	Q8NI60
TKIAHRKSLSQKENR	DLGAP5	21	Q15398
AREKSQAQTLHKVKR	CEP95	756	Q96GE4
VVSKSKEQEHSFKRE	DNAH14	2746	Q0VDD8
KPVNHSTRKEEKQRN	IGHE	261	P01854
HQVSSEKHSRKIQDK	KNDC1	1726	Q76NI1
VKSSKENRKRSQHES	HORMAD1	351	Q86X24
EKKSSISQIHKINRE	CCDC168	2301	Q8NDH2
SSERNVSLTEHKKKQ	FAM186A	91	A6NE01
ERREKIKKSLTSNHQ	CAVIN2	266	O95810
HASVIDSVTKKRQLK	SACS	2781	Q9NZJ4
SKTSRQIKESRSQKH	MTBP	816	Q96DY7
QIKESRSQKHTRILK	MTBP	821	Q96DY7
RKDEKTAQTRESHAK	PACSIN3	161	Q9UKS6
QESQVTSHNKERRSK	RTF1	256	Q92541
IIKSRSDEHNDVQKK	UTRN	21	P46939
DNSAKQTAHNKEKRR	SENP7	236	Q9BQF6
LQTQLSTDTKKDKHR	SEPTIN14	416	Q6ZU15
KSVKHRSNKDNLREA	SYNE2	231	Q8WXH0
VTIKTIKAEEHNKRQ	SEL1L2	16	Q5TEA6
EKTEVSLRNQERKHS	SOCS4	56	Q8WXH5
AHRRNKKDVNLSKTE	SLC9A8	481	Q9Y2E8
KVVTVRHQAVTRKKD	SUPT5H	566	O00267
KTENRRITHISAEQK	MLXIPL	646	Q9NP71
NSVKKAVESKSRHRS	NCAPD3	1356	P42695
RKKREKKAHTSVANN	NKAPD1	251	Q6ZUT1
NSEEHRKKKTSRSRN	NKAPL	171	Q5M9Q1
DDKRARKHVKQDSNV	PIK3R4	841	Q99570
QVKVEKTRHARQASE	TNMD	226	Q9H2S6
HQRVKFTKDHTVRQK	TRIM24	191	O15164
KVNAESVERIKRQHS	TNFRSF11B	231	O00300
VQRSKKQAHRQAEKT	RIBC1	291	Q8N443
SKIRSSREHQFKKDQ	SRGAP3	76	O43295
TKVEHKSNQKERRSL	RELL1	231	Q8IUW5
SKNVQSHRKAEKELT	SYCP2	761	Q9BX26
QGRTDSVEKSKKREH	PRPF38B	476	Q5VTL8
QQAAHTRKKSNRTKS	ZNF256	186	Q9Y2P7
QTERHTKEKRKVTEA	TOPAZ1	111	Q8N9V7
ARQTKQKRKSHSLSI	WDR37	11	Q9Y2I8
ERTNARKKNNHSERK	TOPORS	746	Q9NS56
AVTKNVRHKLTSRNE	VPS13B	1456	Q7Z7G8
TLRSRIDQAQKHSKK	TNNT3	241	P45378
KDTRHQRKNKSKAIS	TYW1	716	Q9NV66
SRKAAQITREAHKQE	TMA16	21	Q96EY4